Delayed wound healing is often a major complication of diabetes considering that the physiological alterations in tissues and cells impair the wound healing process. This may cause additional disease outcomes for example diabetic foot ulcer, a significant reason behind morbidity inside the growing population of diabetic patients.
A new paper finds that topically applied simvastatin accelerates wound healing in diabetic mice, suggesting important implications for humans with diabetes. This research is published from the December issue of The American Journal of Pathology.
Your research was performed by scientists on the Departments of Dermatology and Ophthalmology of Kyoto Prefectural University School of Medicine, Kyoto, Japan; the Department of Dermatology at Hamamatsu University School of Medicine, Hamamatsu, Japan; and Shiseido Innovative Scientific Research Center, Yamamoto, Japan.
“We realize that you have several factors involved with delayed wound healing in diabetes,” says lead investigator Jun Asai, MD, PhD. “These factors include more rapid apoptosis (cell death) and reduced angiogenesis (increase of new arteries and). Impaired lymphangiogenesis, or formation of the latest lymphatic vessels, in addition has recently been established to be a major factor.”
Recent surveys have shown that statins have uses beyond their cholesterol-lowering effects which enable it to stimulate the development of the latest blood vessels when used systemically. These studies tested whether topical putting on simvastatin could promote angiogenesis and lymphangiogenesis during wound healing in genetically diabetic mice. A bonus of topical application is that a suitable concentration of simvastatin may be applied without risk of significant systemic effects such as kidney damage.
The investigators generated a full-thickness skin wound on the backs of diabetic mice. Each wound was addressed with a topical application of either simvastatin in petroleum jelly or petroleum jelly alone. The applying was repeated on days four, seven, and ten.
After a couple weeks, the simvastatin-treated wounds were more than 90% healed, whereas less than 80% were healed from the wounds treated by mineral jelly alone. The main difference in wound closure was greatest on day seven if your simvastatin-treated wounds were 79.26% healed weighed against 52.45% in the control group.
“Our results suggested to us that the mechanisms underlying the lymphangiogenic results of simvastatin in lymphatic endothelial cells (LECs) could be a lot like those for angiogenic effects,” comments Dr Asai. “However, not like our expectation, simvastatin would not promote proliferation of human LECs in vitro. We therefore investigated other possible causes of lymphangiogenic factors.”
Earlier reports suggested that infiltrating macrophages help with lymphangiogenesis because the major producer of vascular endothelial growth factor C (VEGF-C) in cutaneous wound healing. In this particular study, how many infiltrating macrophages in granulation was significantly increased by topical use of simvastatin, and a lot of such macrophages produced VEGF-C.
“These studies demonstrates that topical simvastatin significantly accelerates wound recovery by increasing both angiogenesis and lymphangiogenesis. Our observations report that the good results of simvastatin on lymphangiogenesis are due both to some direct influence on lymphatics and indirect effects via macrophages homing towards wound. This is the simple strategy which could have significant therapeutic prospect of enhancing wound healing in patients with impaired microcirculation, including that in diabetes. Further investigation is required to determine its clinical utility”, concludes Dr Asai.
Source: Elsevier Health Sciences
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.None found.